Pegylated-Interferon .Alfa. 2B (Peg-Ifn)
Fibrotic Liver Disease
Explore 26 assets in Fibrotic Liver Disease →Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Third Affiliated Hospital, Sun Yat-Sen University
Modality
protein_peptide
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03919565CT.gov Optimized Treatment of Peginterferon Alfa 2a/2b in Anti-virus Treatment Naive Patients With HBV Related Liver Fibrosis | — | Unknown | — | — | — |
NCT03920605CT.gov Optimized Treatment of Peginterferon Alfa 2a/2b in Treatment Experienced Patients With HBV Related Liver Fibrosis | — | Unknown | — | — | — |
NCT00323804CT.gov Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy. | — | Completed | — | — | — |
NCT00049842CT.gov Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Fibrotic Liver Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pegylated-Interferon .Alfa. 2B (Peg-Ifn) (this asset) | Third Affiliated Hospital, Sun Yat-Sen University | P3 | BB · 64 |
| Entecavir | Tanta University | P4 | BB |
| Colchicinum | Zagazig University | P4 | BB |
| Peg-Intron | Beth Israel Deaconess Medical Center | P4 | BB |
| Peg-Ifn | Beijing Friendship Hospital | P4 | BB |
| Hydronidone | Beijing Continent Pharmaceutical Co, Ltd. | P3 | BB |
| Ribavirin | ANRS, Emerging Infectious Diseases | P3 | BB |
| A Therapeutic Pegylated Fibroblast Growth Factor 21 Agonist/Mimetic Which Restores Leptin Responsiveness | Bristol-Myers Squibb | P2 | BB |
| Losartan | Hospital Clinic of Barcelona | P4 | BB |
+42 more in the Fibrotic Liver Disease cohort
Other indications for Pegylated-Interferon .Alfa. 2B (Peg-Ifn)
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Hepatitis C Virus Infection | — | P3 | BBB · 73 |
| Hepatitis C Virus Infection | — | P4 | BB · 70 |
| Cirrhosis Of Liver | — | P3 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pegylated-Interferon .Alfa. 2B (Peg-Ifn) in Fibrotic Liver Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pegylated-interferon-alfa-2b-peg-ifn-fibrotic-liver-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →